265
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Outcome of continued infliximab therapy in Crohn’s disease patients with response but without remission after one year of infliximab – a retrospective cohort study

, , , , &
Pages 930-937 | Received 12 Mar 2018, Accepted 21 May 2018, Published online: 10 Jul 2018
 

Abstract

Background: Optimal management of Crohn’s disease patients having responded to infliximab but without achieving remission is not well defined. The present study examined if these patients benefit from continued long-term infliximab maintenance therapy.

Method: Retrospective cohort study including all patients treated with infliximab for 1 year until the end of 2017 who have had a response but not reached remission on infliximab. Clinical outcomes were defined by the physicians’ global evaluation, supported by clinical indices and objective markers of disease activity.

Results: In total, 376 Crohn’s disease patients received infliximab. Among these, 76 (20%) were classified as having response but non-remission (RNR) after 1 year of therapy. A great majority (n = 54; 71%) experienced no additional therapeutic benefit after a further year of infliximab maintenance therapy, thus still having RNR. Nineteen patients (25%) obtained remission during continued infliximab, whereas only 4% (n = 3) experienced treatment failure. Although infliximab therapy beyond 2 years (follow-up median 35 months, IQR: 23–55) was accompanied by a higher proportion attaining remission (40%), nearly half (46%) still failed to improve. Among patients who had discontinued infliximab while having RNR (n = 21), half (n = 11) experienced disease flare within five months (median 22 weeks, IQR: 12–31).

Conclusion: Most patients (71%) had no additional therapeutic benefit after an additional year of infliximab therapy, and after a median maintenance infliximab treatment period of 3 years, half still failed to improve further. Considering the importance of achieving complete remission, these patients appear to have an unmet medical need.

Acknowledgments

This study was supported by a grant from Takeda pharmaceuticals, Denmark. The authors would like to thank Tobias WirenfeldtKlausen, Department of Hematology, Herlev and Gentofte Hospital, Denmark, for statistical support. Further, they also would like to thank Nils Bolstad and David J Warren, Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, for measurement of infliximab concentrations.

Disclosure statement

This study was in part supported by a grant from Takeda. S. Buhl has served as speaker for Janssen and as a consultant for Takeda. J. Brynskov has served as advisory board member for Abbvie, MSD, Takeda and Janssen; and as Primary investigator for Abbvie, Quintiles and Janssen. C Steenholdt, M. Borghede, M. Rasmussen, and M.A. Ainsworth have no interests to declare.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 336.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.